Results 31 to 40 of about 5,314 (201)

New perspectives for preventing hepatitis C virus liver graft infection [PDF]

, 2016
publisher: Elsevier articletitle: New perspectives for preventing hepatitis C virus liver graft infection journaltitle: The Lancet Infectious Diseases articlelink: http://dx.doi.org/10.1016/S1473-3099(16)00120-1 content_type: article copyright: © 2016 ...
Abdelmalek, Adam, Akazawa, Andre, Audrey Coilly, Bandiera, Bankwitz, Baumert, Benedicto, Berenguer, Berenguer, Berenguer, Berenguer, Bizollon, Blasco, Brown, Bzowej, Carrion, Carrion, Carrion, Chalasani, Charlton, Charlton, Charlton, Charlton, Chung, Ciesek, Coilly, Coilly, Coilly, Colpitts, Colpitts, Crespo, Curry, Curry, Daniel J Felmlee, Davis, de Jong, Denniston, Desombere, Deuffic-Burban, Didier Samuel, Fafi-Kremer, Faisal, Fauvelle, Feld, Felmlee, Firpi, Fofana, Fofana, Fofana, Forman, Forns, Forns, Foster, Foster, Fukasawa, Fukuhara, Gambato, Gane, Gane, Gerold, Guedj, Haberstroh, Haid, He, Helle, Hopcraft, Janssen, Ji, Jiang, Keck, Khan, Kim, Kong, Kugelmas, Kwo, Kwo, Lanford, Law, Leroy, Lin, Lupberger, Mailly, Manns, Manns, Marino, Martin, Martin, Masaki, Mazzaferro, Meuleman, Meuleman, Meuleman, Munoz, O'Shea, Ojo, Ouwerkerk-Mahadevan, Owsianka, Pawlotsky, Perin, Picciotto, Ploss, Ploss, Poordad, Prieto, Pungpapong, Raymond T Chung, Reddy, Roche, Rowe, Rowe, Sainz, Shergill, St Vincent, Sugawara, Sulkowski, Takaki, Terrault, Thomas F Baumert, Toso, Uprichard, Van Der Ree, Vanwolleghem, Veldt, Vercauteren, Vercauteren, von Hahn, Walter, Wang, Watt, Wedemeyer, Welker, Xiao, Xiao, Xirouchakis, Yamashita, Zahid, Zeisel, Zeisel, Zhang, Zhang, Zhu, Zona   +143 more
core   +4 more sources

Use of glecaprevir and pibrentasvir as rescue therapy in patients with resistance to direct-acting antiviral agents

Annals of Hepatology, 2022
Introduction and Objective: Hepatitis C virus infection is one of the main causes of chronic liver disease. Treatment with direct-acting antivirals (DAAs) has shown high efficacy in achieving sustained viral response with a low risk of relapse. There are
LS Juarez Chavez, JS Sandoval Mendoza
doaj   +1 more source

Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study [PDF]

, 2017
Background and aims Chronic hepatitis C virus (HCV) genotype 3 infection with advanced liver disease has emerged as the most challenging to treat. We retrospectively assessed the treatment outcome of sofosbuvir (SOF) based regimes for treatment of HCV ...
Balslev, Ulla, Belard, Erika, Dalgard, Olav, Farkkila, Martti, Hallager, Sofie, Heggelund, Lars, Karlsen, Lars, Kjaer, Mette Skalshoi, Krarup, Henrik, Lagging, Martin, Laursen, Alex Lund, Madsen, Lone G., Noraberg, Geir, Ovrehus, Anne, Roge, Birgit Thorup, Weiland, Ola, Weis, Nina   +16 more
core   +4 more sources

Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: A systematic review and meta-analysis

Journal of Infection and Public Health, 2018
Velpatasvir is a newly FDA-approved inhibitor of hepatitis C virus (HCV) NS5A protein. We performed this systematic review and meta-analysis to investigate the safety and efficacy of velpatasvir plus sofosbuvir in the treatment of chronic HCV infection ...
Hussien Ahmed, Abdelrahman I. Abushouk, Attia Attia, Mohamed Gadelkarim, Mohamed Gabr, Ahmed Negida, Mohamed M. Abdel-Daim   +6 more
doaj   +1 more source

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries

Journal of Virus Eradication, 2020
Objectives: Seven years after the introduction of direct-acting antivirals (DAAs) for the treatment of hepatitis C, high prices remain a barrier for treatment programs worldwide.
Melissa J. Barber, Dzintars Gotham, Giten Khwairakpam, Andrew Hill   +3 more
doaj   +1 more source

‘It’s been a long haul, a big haul, but we’ve made it’: hepatitis C virus treatment in post-transplant patients with virus recurrence: An interpretative phenomenological analysis [PDF]

, 2018
The lived experience of both interferon-based and new interferon-free treatments in patients with hepatitis C virus remains understudied. To explore their journey through hepatitis C virus treatment, we interviewed seven post-transplant patients with ...
Chouliara, Zoe, Dickson, Adele, Flowers, Paul, Hayes, Peter, Krzeczkowska, Anna   +4 more
core   +3 more sources

Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience

Infection and Drug Resistance, 2021
Qiao Tang, Li Wei, Xiaoqing Liu, Peng Hu Department of Infectious Diseases, Institute for Viral Hepatitis, The Key Laboratory of Molecular Biology for Infectious Diseases, Chinese Ministry of Education, The Second Affiliated Hospital of Chongqing Medical
Tang Q, Wei L, Liu X, Hu P
doaj  

NS5A Resistance-Associated Substitutions in Patients with Genotype 1 Hepatitis C Virus:Prevalence and Effect on Treatment Outcome [PDF]

, 2017
Background & Aims The efficacy of NS5A inhibitors for the treatment of patients chronically infected with hepatitis C virus (HCV) can be affected by the presence of NS5A resistance-associated substitutions (RASs).
Brainard, Diana M, Chuang, Wan-Long, Doehle, Brian, Dore, Gregory J, Dvory-Sobol, Hadas, Han, Kwang-Hyub, Hedskog, Charlotte, Jacobson, Ira, Knox, Steven, Mangia, Alessandra, Martin, Ross, McHutchison, John G, Miller, Michael D., Mizokami, Masashi, Mo, Hongmei, Pianko, Stephen, Sulkowski, Mark, Svarovskaia, Evguenia, Yun, Chohee, Zeuzem, Stefan   +19 more
core   +2 more sources

Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16–24 weeks

Journal of Virology
The outcomes of retreatment patients infected with hepatitis C virus genotype 3, cirrhosis, with velpatasvir may be affected by treatment failure with velpatasvir. The efficacy of SOF+GLE/PIB+RIB 16–24 weeks of treatment has been shown.
Sergii V. Fedorchenko, Zhanna Klimenko, Tatiana Martynovich, Iryna Solianyk, Tatiana Suprunenko   +4 more
doaj   +1 more source

Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates [version 1; peer review: 2 approved]

F1000Research, 2020
We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CLpro) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and
Yu Wai Chen, Chin-Pang Bennu Yiu, Kwok-Yin Wong   +2 more
doaj   +1 more source